Skip to main content

Advertisement

Table 2 Pathologic response following neoadjuvant therapy

From: Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer

  Neoadjuvant chemotherapy Neoadjuvant SBRT (dose / fractions) Pathologic response (Evans’ criteria)
01 Gem./Cape. 36 Gy / 3 IV
02 Gem./Cape. 36 Gy / 3 IV
03 FOLFIRINOX, Gem./Abraxane 36 Gy / 3 IV
04 Gem./Erlotinib 24 Gy / 1 III
05 Gem./Cape. 24 Gy / 1 III
06 Gem. 24 Gy / 1 IIb
07 FOLFIRINOX 36 Gy / 3 IIb
08 N/A 36 Gy / 3 IIa
09 Gem./Cape. 36 Gy / 3 IIa
10 Gem./Cape. 24 Gy / 1 IIa
11 Gem./Cape. 24 Gy / 1 IIa
12 Gem./Cape. 30 Gy /3 IIa
  1. 25% of patients achieved a complete pathologic (pCR) response to neoadjuvant therapy (Evans’ grade: IV), and an additional 16.7% of patients had >90% tumor cell destruction (Evans’ grade: III). In total, 58.3% of patients had at least 50% of tumor cell destruction (Evans’ Grade: IIb – IV). For those achieving pCR, SBRT dose was 36 Gy in 3 fractions and neoadjuvant chemotherapy was gemcitabine-based. [Abbreviations: Gem Gemcitabine, Cape Capecitabine].